Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells

Biochemical Pharmacology

Volumn 53, Issue 4, 1997, Pages 461-470

  Parekh, Hemant ^a   Wiesen, Kenneth ^a   Simpkins, Henry ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ovarian tumor cells; P gp and non P gp mediated; taxol resistance

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN; PACLITAXEL; VERAPAMIL; VINCRISTINE;

ARTICLE; CARCINOMA CELL; CELL CLONING; CONTROLLED STUDY; CROSS RESISTANCE; CYTOCHEMISTRY; DRUG ACCUMULATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031581815     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)83383-7     Document Type: Article

References (47)

1. 1. Rowinsky EK, Onetto N, Canetta RM and Arbuck SG, Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 19: 646-662, 1992.
2. 2. Rowinsky EK and Donehower RC, The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20: 16-25, 1993.
3. 3. Trimble EL, Arbuck SG and McGuire WP, Options for primary chemotherapy of epithelial ovarian cancer: Taxanes. Gynecol Oncol 55: S114-S121, 1994.
4. 4. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
5. 5. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB, Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. Br J Cancer 68: 1104-1109, 1993.
6. 6. Horwitz SB, Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136, 1992.
7. 7. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP, Taxol: Mechanisms of action and resistance. Monogr Natl Cancer Inst 15: 55-61, 1993.
8. 8. Combeau C, Commercon A, Mioskowski C, Rousseau B, Aubert F and Goeldner M, Predominant labelling of β-over α-tubulin from porcine brain by a photoactivable taxoid derivative. Biochemistry 33: 6676-6683, 1994.
9. 9. Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr GA and Horwitz SB, 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 ammo acids of β-tubulin. J Biol Chem 269: 3132-3134, 1994.
10. 10. Rowinsky EK, Donehower RC, Jones RJ and Tucker RW, Microtuble changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48: 4093-4100, 1988.
11. 11. Roberts JR, Allison DC, Donehower RC and Rowinsky EK, Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50: 710-716, 1990.
12. 12. Jordan MA, Toso RJ, Thrower D and Wilson L, Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
13. 13. Lopes NM, Adams EG, Pitts TW and Bhuyan BK, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235-242, 1993.
14. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 54: 4355-4361, 1994.
15. 15. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
16. 16. Bradley G and Ling V, P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223-233, 1994.
17. 17. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G and Willingham MC, Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8: 465-475, 1994.
18. 18. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KG, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG, Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
19. 19. Batrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH and Twentyman PR, A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110-117, 1994.
20. 20. Zaman GJ, Flens MJ and van Leusden MR, The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
21. 21. Cole SP, Sparks KE and Fraser K, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
22. 22. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA and Kruh GD, Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347, 1995.
23. 23. Roy SN and Horwitz SB, A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45: 3856-3863, 1985.
24. 24. Keates RAB, Sarangi F and Ling V, Structural and functional alterations in microtubule protein from Chinese hamster ovary cell mutants. Proc Natl Acad Sci USA 78: 5638-5642, 1981.
25. 25. Houghton JA, Houghton PJ, Hazelton BJ and Douglass EC, In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45: 2706-2712, 1985.
26. 26. Cabral F and Barlow SB, Mechanisms by which mammalian cells acquire resistance to drugs that affect microtuble assembly. FASEB J 3: 1593-1599, 1989.
27. 27. Minotti AM, Barlow SB and Cabral F, Resistance to antimitotic drugs in Chinese hamster ovary tumor cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266: 3987-3994, 1991.
28. 28. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M and Saijo N, Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85: 290-297, 1994.
29. 29. Debal V, Allam N, Morjani H, Millot JM, Braguer D, Breillout F and Manfait M, Characterization of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 70: 1118-1125, 1994.
30. 30. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD and Horwitz SB, Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269-31275, 1995.
31. 31. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L and Sikic BI, Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091-1097, 1996.
32. 32. Parekh HK and Simpkins H, Species-specific differences in taxol transport and cytotoxicity against human and rodent tumor cells: Evidence for an alternate transport system? Biochem Pharmacol 51: 301-311, 1996.
33. 33. Chen C-J, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB, Internal duplication and homology with bacterial transport protein in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986.
34. 34. Futscher BW, Abbaszadegan MR, Domann F and Dalton WS, Analysis of MRP mRNA in mitoxantrone-selected multidrug-resistant human tumor cells. Biochem Pharmacol 47: 1601-1606, 1994.
35. 35. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D and Gekeler V, Expression of mdr1, mrp, topoisomerase II α/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 89: 356-363, 1995.
36. 36. Tiwari SC and Suprenant KA, A pH-and temperature-dependent cycling method that doubles the yield of microtubule protein. Anal Biochem 215: 96-103, 1993.
37. 37. Parekh H and Simpkins H, Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemother Pharmacol 37: 457-462, 1996.
38. 38. Crossin KL and Carney DH, Microtuble stabilization by taxol inhibits initiation of DNA synthesis by thrombin and epidermal growth factor. Cell 21: 341-350, 1981.
39. 39. Verlhac MD, de Pennart H, Maro B, Cobb MH and Clarke HJ, MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes. Dev Biol 58: 330-340, 1993.
40. 40. Ding AH, Porteu F, Sanchez E and Nathan CF, Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248: 370-372, 1990.
41. 41. Manthey CL, Brandes ME, Perera PY and Vogel SN, Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 149: 2459-2465, 1992.
42. 42. Haldar S, Chintapalli J and Croce CM, Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
43. 43. Lee L-F, Schuerer-Maly C-C, Lofquist AK, van Haaften-Day C, Ting JP-Y, White CM, Martin BK and Haskill JS, Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res 56: 1303-1308, 1996.
44. WAF1 and p53 requires c-raf-1. Cancer Res 55: 4623-4626, 1995.
45. 2/M arrest apoptosis. Nature Med 2: 72-79, 1996.
46. 46. Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR and Howell SR, In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92: 431-440, 1993.
47. 47. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Ramaguera J, North L, Mansfield P, Callendar D, Mesina O and Cabanillas F, Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14: 233-239, 1996.